• Publications
  • Influence
Infliximab, azathioprine, or combination therapy for Crohn's disease.
TLDR
Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or inflIXimab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azATHioprine monotherapy.
Infliximab for induction and maintenance therapy for ulcerative colitis.
TLDR
Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Inflammatory bowel disease: clinical aspects and established and evolving therapies
TLDR
The current diagnostic approach, their pathology, natural course, and common complications, the assessment of disease activity, extraintestinal manifestations, and medical and surgical management are discussed, and diagnostic and therapeutic algorithms are provided.
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
TLDR
Adalimumab was well-tolerated, with a safety profile consistent with previous experience with the drug, and was significantly more effective than placebo in maintaining remission in moderate to severe CD through 56 weeks.
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
TLDR
Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis and the frequency of adverse events was similar in the vedolIZumab and placebo groups.
Vedolizumab as induction and maintenance therapy for Crohn's disease.
TLDR
Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolIZumab (rather than switching to placebo) were morelikely to be in remission at week 52.
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
TLDR
Colorectal neoplasia develops in a substantial fraction and overall survival is worse and PSC-IBD may represent a distinct IBD phenotype.
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000
TLDR
The incidence rates of CD and UC increased after 1940, they have remained stable over the past 30 years, and there were 1.1 million people with inflammatory bowel disease in the US in 2000.
Infliximab for the treatment of fistulas in patients with Crohn'S disease.
TLDR
In patients with active CD, adalimumab therapy was more effective than placebo for inducing fistula healing and complete fistula Healing was sustained for up to 2 years by most patients in an open-label extension trial.
Natalizumab induction and maintenance therapy for Crohn's disease.
TLDR
Induction therapy with natalizumab for Crohn's disease resulted in small, nonsignificant improvements in response and remission rates, which will need to be weighed against the risk of serious adverse events.
...
1
2
3
4
5
...